Credit Suisse raised the price target for the Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock to “a Neutral”. The rating was released on April 26, 2021. We previously noted in another research note published on January 12, 2021 by Citigroup that downgraded the stock from a Buy to a Neutral with a price target of $108 for SRPT stock. In their research brief published January 08, 2021, Morgan Stanley analysts downgraded the Sarepta Therapeutics Inc. stock from Overweight to Equal-Weight with a price target of $95.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$2.1 during the last quarter as opposed to a consensus estimate of -$1.77, which indicates the company missed its estimate by -$0.33, which implies that the company surprised the market by -18.60%. It appears that the average earnings per share estimate for the current quarter (ending in Jun 2021) is -$1.19. This is an average of 12 analysts’ earnings, where the high earnings per share estimate is -$0.19 and the low earnings per share estimate is -$2.32. According to 15 analyst estimates, an average revenue estimate of $163.04M is projected for the current quarter with a high revenue estimate of $253.75M and a low estimate of $129M.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Sarepta Therapeutics Inc. (NASDAQ:SRPT) raised 2.55% to close Thursday’s market session at $76.86, higher as compared to yesterday’s close. The stock price fluctuated between $73.19 and $77.00 throughout the trading session with the volume trading being 4641213 shares, which represented a significant variation when compared to the three months average volume of 1.14 million shares. The firm’s stock price fluctuated -4.18% within the last five trades and 9.72% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -43.11% in the last 6 months and -11.72% was subtracted to its value over the previous 3 months. SRPT stock is trading at a margin of 2.52%, 3.22% and -33.63% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, SRPT deals in the Healthcare domain. The stock is trading -57.73 percent below its 52-week high and 13.56 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -18.41. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Sarepta Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $6.18 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 10.78 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 11.40, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 4.70 percent of Sarepta Therapeutics Inc. shares are owned by insiders, and 83.70 percent are held by financial institutions. BEHRENS M KATHLEEN, the Director at Sarepta Therapeutics Inc. (SRPT) has sold 5,000 shares of firm on Mar 10 at a price of $85.76 against the total amount of $0.43 million. In another inside trade, Wigzell Hans Lennart Rudolf, Director of Sarepta Therapeutics Inc. (NASDAQ:SRPT) sold 10,000 shares of the firm on Mar 08 for a total worth of $0.84 million at a price of $83.51. An inside trade which took place on Dec 11, Principal Financial Officer of Sarepta Therapeutics Inc. Bratica Joseph sold 1,115 shares of firm against total price of $0.18 million at the cost of $165.00 per share.